DAX ®11.641,45+0,76%TecDAX ®2.659,27+0,34%S&P FUTURE2.776,80+0,34%Nasdaq 100 Future7.152,25+0,64%
finanztreff.de

DGAP-Adhoc: Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of 300,019 shares from the current cash capital increase and signs a Term Sheet for financing facility of up to EUR 11 Million

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 6 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Capital
Increase/Miscellaneous
Elanix Biotechnologies AG: Elanix Biotechnologies AG places a total of
300,019 shares from the current cash capital increase and signs a Term Sheet
for financing facility of up to EUR 11 Million

14-Feb-2018 / 11:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

*The information in this announcement is NOT for publication OR distribution
in or into the United States of America, Australia, Canada or any
jurisdiction in which such distribution or publication could be unlawful*

*Elanix Biotechnologies AG places a total of 300,019 shares from the current
cash capital increase and signs a Term Sheet for financing facility of up to
EUR 11 Million*

Berlin, 14 February 2018 - Elanix Biotechnologies AG ("Elanix"; "the
company"), a developer of tissue regeneration products and specialty
cosmetics in the field of dermatology and gynecology, announces the
completion of the capital increase approved by the General Shareholder
Assembly ("GSM") on 24 August 2017. A total of 300,019 offered shares were
placed at a subscription price of EUR 3.75 resulting in gross proceeds of
EUR 1.125 million. As a result of the cash capital increase, the share
capital of Elanix will increase to a total of 7,099,219 shares. Among other
things, the gross proceeds will be used for the market launch of
SKINrepair(R) as well as for the further development and regulatory approval
of First Cover, a product for the treatment of burn wounds.

A leading institutional investor approached during this capital increase has
indicated that they intend to invest in Elanix at a later stage this year.
Elanix and the investor have negotiated and signed a corresponding Term
Sheet, according to which, Elanix would have access up to EUR 11 million
over the next three years as part of a financing mix to finance further
growth. A detailed contract is to be negotiated and signed in the coming
weeks.

Tomas Svoboda, CEO

*About Elanix*

Elanix develops and commercializes tissue regeneration products for acute
wound care, dermatological and gynecological applications, and provides
services in cell technologies. The company was founded in 2012 as a spin-out
from the University Hospital of Lausanne (CHUV), Switzerland, to
commercialize a patented human progenitor cell technology. Progenitor cells
are fully differentiated yet immunologically neutral cells that are very
potent inducers of tissue growth and healing. Elanix owns GMP certified
Master and Working human cell banks with vast quantities of cells.

Elanix has registered headquarters in Berlin, Germany, with offices in
Wiesbaden, Germany and Nyon, Switzerland. It is listed in the Regulated
Market on the Frankfurt Stock Exchange under the symbol ELN.F. For more
information and updates, visit www.elanixbiotechnologies.com.

*Press Contacts*

Elanix Biotechnologies Halsin Partners
Tomas Svoboda, CEO Mike Sinclair
Tel: +41 (0)22 363 66 40 Tel: +44 (0)20 7318 2955
investor.relations@elanix-bt.com msinclair@halsin.com

*Forward-looking statements*

This publication may contain certain forward-looking statements regarding
the Company and its business activities. Such statements may involve certain
risks, uncertainties and other factors which can lead to the results,
financial situation, performance and success of the Company differing
significantly in reality from what is expressed or implied by such
statements. The reader should therefore not place undue trust in these
statements, especially in connection with contracts and investment
decisions. The Company does not accept any obligation to update such
forward-looking statements.

*Disclaimer*

This communication may not be published or distributed in the United States
of America (including its territories and possessions), Canada, Japan or
Australia or in any other countries in which such publication and
distribution might be illegal. The distribution of this publication may be
subject to legal restrictions in some countries; anyone in possession of
this document or of the information referred to in it should obtain
information regarding such restrictions and adhere to them. Non-adherence to
such restrictions may constitute a breach of capital market law in such
countries.

This communication is neither an offer nor an invitation to subscribe for or
purchase shares of Elanix Biotechnologies AG in the United States of
America, Germany or any other country. Neither does this communication
constitute a prospectus under Directive 2003/71/EC of the European
Parliament and Council dated 4 November 2003 as amended (the "Prospectus
Directive"). The public offering in Germany is carried out solely by means
of and based on the share prospectus approved by the Federal Supervisory
Financial Authority (BaFin). This share prospectus is published on the
Elanix Biotechnologies AG website
(https://elanixbiotechnologies.com/Investor Relations). Any investment
decision relating to Elanix Biotechnologies AG subscription rights or shares
should be made based on the prospectus.

Neither this publication nor its content may be used as a basis for an offer
in any country. The shares referred to above may be neither sold nor offered
in the United States of America insofar has no registration has been
undertaken or insofar as no exception from the registration requirement
applies under the United States Securities Act of 1933 as last amended
("Securities Act"). Elanix Biotechnologies AG shares are not and will not be
registered according to the Securities Act.

This communication does not constitute a recommendation relating to the
placement of the shares described in this notice. Investors should consult a
professional advisor in determining the suitability of the offer to the
individual concerned.

In the United Kingdom, this publication is only intended for (i)
professional investors who fall under Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended
(hereinafter referred to as "Order") or (ii) persons who fall under Article
49(2) (a) to (d) of the Order (high net worth companies, private companies,
etc.) (such persons are referred to collectively hereinafter as "Relevant
Persons"). Persons other than Relevant Persons may not refer to this
publication or rely on it. Any investment or potential investment referred
to in this publication is solely open to Relevant Persons and is only
entered into by Relevant Persons.

In member states of the European Economic Area which have implemented the
Prospectus Directive (the "Relevant Member States"), this publication and
any subsequent offer is aimed solely at "qualified investors" as defined by
the Prospectus Directive. For these purposes, "Prospectus Directive" refers
to Directive 2003/71/EC (including all amendments, in particular Directive
2010/73/EU) and includes all relevant implementation measures in the
Relevant Member States.

No measures have been taken that would allow the shares to be offered or
purchased or this publication to be distributed in countries in which this
is not permitted. Anyone coming into possession of this publication must
obtain information regarding any restrictions themselves and observe these
accordingly.

14-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Elanix Biotechnologies AG
Kurfürstendamm 32
10719 Berlin
Germany
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated
Unofficial Market in Berlin, Dusseldorf

End of Announcement DGAP News Service

654161 14-Feb-2018 CET/CEST



(END) Dow Jones Newswires

February 14, 2018 05:01 ET ( 10:01 GMT)
Werbung

Das könnte Sie auch interessieren

Werbung
Werbung

News-Suche

Suchbegriff:
Werbung
Werbung

Werbung
Börse Stuttgartschliessen
Börse Stuttgart

Gewinnen Sie pures Gold!

Unter allen Teilnehmern an der Anlegerumfrage verlost der Börse Stuttgart Anlegerclub Gold im Gesamtwert von über 1000 Euro.

Jetzt kostenlos anmelden und mitmachen!
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 43 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen
schliessen